Intra Artherial Therapies in Treatment of Primary Liver Diseases: an Observational Study

This study is non profit, observational, retrospective, prospective and single institution.

The researchers will do a retrospective and prospective data collection and analyze the results. They will examine the radiological images (CT scan and RM) to assess the type and size of the cancer, track how the disease responds to treatments, identify possible complications.

There are no drugs involved and all the intra arterial therapies are performed within the routine clinical-care path.

• For the retrospective phase the researchers will analyze radiological image of the participants that received a intra arterial therapy from the 1st of January 2009. It's expected to enroll around 2000 participants.
• For the prospective phase the researchers will enroll for 5 years eligible participants that will receive a intra arterial therapy. Participants will go through a follow up every three months for the duration of the whole study. It is expected to enroll around 1300 participants.

Inclusion criteria

• diagnosis of Hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) and clinical indication to receive or have already received one of the following treatments:

• Trans-arterial embolization (TAE),
• Transarterial chemoembolization (TACE),
• Transarterial radioembolization (TARE)
• Drug-eluting beads chemoembolization (DEB-TACE)
• Age over 18
• To give informed consent

Exclusion criteria

• shunt of gastro intestinal arteries that cannot be embolized
• metastasis spread outside of the liver
• liver failure